<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: Prothrombin G20210A</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: Prothrombin G20210A</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: Prothrombin G20210A</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2760082568"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph discusses interpretation and possible interventions for genetic testing that reveals the G20210A variant in the <em>F2</em> gene, which encodes prothrombin, also called prothrombin gene mutation (PGM). It does not<strong> </strong>discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately in UpToDate [<a href="#rid1">1</a>]. (See <a class="local">'UpToDate topics'</a> below.)</p><p class="headingAnchor" id="H1155952074"><span class="h1">OVERVIEW OF CLINICAL IMPLICATIONS</span></p><p class="headingAnchor" id="H3979020413"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>Prothrombin G20210A is a point mutation in the 3' untranslated region of the <em>F2</em> gene, which encodes prothrombin (factor II). </p><p>The variant may also be called [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin gene mutation (PGM)</p><p class="bulletIndent1"><span class="glyph">●</span><em>F2</em> G20210A or 20210G&gt;A</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin G20210A or 20210G&gt;A</p><p class="bulletIndent1"><span class="glyph">●</span>Factor II c.*97G&gt;A</p><p></p><p>There is no protein sequence change because the variant affects a noncoding region of the gene.</p><p>Prothrombin G20210A is often the only variant tested in <em>F2</em>. Rarely, other <em>F2</em> variants may be identified; clinical implications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Other prothrombin gene variants'</a>.)</p><p>The checklist provides important caveats (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1063995536"><span class="h2">Clinical significance (VTE risk)</span><span class="headingEndMark"> — </span>In normal clotting, prothrombin (factor II) is cleaved to thrombin, the final enzyme in the enzymatic cascade that converts fibrinogen to fibrin in the fibrin clot (<a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 1</a>). The G20210A variant leads to increased prothrombin and prothrombin activity and is a risk factor for venous thromboembolism (VTE).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterozygosity</strong> – Heterozygosity for prothrombin G20210A confers an approximately three- to fourfold increased risk for VTE (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>). Typical sites include deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral vein thrombosis (CVT; especially in women taking estrogen-containing contraceptives), and portal or hepatic vein thrombosis.</p><p></p><p class="bulletIndent1">Heterozygosity for prothrombin G20210A is highly prevalent in certain populations (frequency, 1 to 4 percent). Most of these individuals are unaware they carry the variant and will never develop VTE. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homozygosity and double heterozygosity</strong> – Homozygosity for prothrombin G20210A and double heterozygosity for prothrombin G20210A plus another thrombophilia variant are infrequent and carry a higher risk. </p><p></p><p class="bulletIndent1">We do not routinely test for other variants in asymptomatic individuals, but many individuals who have had thrombophilia testing following a thrombotic event will have this information available. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Risk of VTE'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other VTE risk factors</strong> – VTE risk may also be increased by other inherited and acquired risk factors (see  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior personal history of VTE</p><p class="bulletIndent2"><span class="glyph">•</span>Other thrombophilic variants (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Acquired VTE risk factors (estrogen therapy, pregnancy, immobility, trauma, surgery, acute or chronic medical illnesses)</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of VTE, especially if unprovoked.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy morbidity</strong> – An association between prothrombin G20210A and early pregnancy morbidity is controversial. (See <a class="local">'Pregnancy morbidity'</a> below.)</p><p></p><p class="headingAnchor" id="H1408649755"><span class="h1">ASYMPTOMATIC INDIVIDUALS (NO PRIOR VTE)</span></p><p class="headingAnchor" id="H2148621839"><span class="h2">VTE risk reduction</span><span class="headingEndMark"> — </span>The risk of a first venous thromboembolic (VTE) event is determined by many factors besides an individual's <em>F2</em> genotype. These other factors should be considered when determining the appropriate risk reduction strategy, regardless of whether the individual carries the prothrombin G20210A variant. (See <a class="local">'Clinical significance (VTE risk)'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterozygous individuals</strong> – Our approach to VTE risk reduction in individuals who are heterozygous for prothrombin G20210A is similar to the general population, with a few differences (<a class="graphic graphic_table graphicRef122639" href="/z/d/graphic/122639.html" rel="external">table 3</a>), as shown in the flowchart (<a class="graphic graphic_algorithm graphicRef123067" href="/z/d/graphic/123067.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We are more likely to use prophylactic anticoagulation for certain surgeries. (See <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We advise avoiding estrogen-containing contraceptives. </p><p></p><p class="bulletIndent2">We encourage alternative methods if contraception is desired or alternative treatments for other conditions such as dysmenorrhea or acne. (See <a class="local">'Estrogen-containing contraceptives'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We are more likely to use anticoagulation during pregnancy and postpartum if other risk factors are present. (See <a class="local">'Pregnancy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homozygous/double heterozygous individuals</strong> – For rare individuals who are homozygous for prothrombin G20210A or double heterozygous for prothrombin G20210A and another thrombophilia variant, VTE risk is higher (<a class="graphic graphic_table graphicRef119942" href="/z/d/graphic/119942.html" rel="external">table 4</a>). This still translates to a relatively low overall incidence of VTE (&lt;1 percent per year), and we generally do not chronically anticoagulate these individuals. </p><p></p><p class="bulletIndent1">However, anticoagulation may be considered in those with a very strong family history of VTE and/or those who place an especially high value on preventing thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Biology of the mutation and mechanism of increased thrombosis risk'</a>.)</p><p></p><p class="headingAnchor" id="H1569156729"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Surgery confers an increased risk for VTE independent of other risk factors; prothrombin G20210A may further increase this risk. </p><p>We generally treat individuals with prothrombin G20210A as a high-risk group when deciding about postoperative VTE prophylaxis, and we are more likely to prophylactically anticoagulate rather than use other modalities such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or intermittent pneumatic compression devices alone for surgeries in which postoperative VTE is considered. The variant does not affect the choice or dosing of the anticoagulant.</p><p>Supporting evidence, anticoagulant dosing, and other recommendations are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a> and  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H505567369"><span class="h3">Estrogen-containing contraceptives</span><span class="headingEndMark"> — </span>Estrogen-containing contraceptives carry an increased risk of VTE independent of other risk factors, and the risk is significantly increased by prothrombin G20210A (<a class="graphic graphic_table graphicRef119942" href="/z/d/graphic/119942.html" rel="external">table 4</a>). </p><p>However, avoiding estrogen-containing contraceptives must be balanced with the risk of unintended pregnancy, which also increases VTE risk.</p><p class="bulletIndent1"><span class="glyph">●</span>We avoid estrogen-containing contraceptives in individuals with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Homozygosity for prothrombin G20210A</p><p class="bulletIndent2"><span class="glyph">•</span>Double heterozygosity for prothrombin G20210A and another thrombophilic variant (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Heterozygosity for prothrombin G20210A and a personal history of VTE</p><p class="bulletIndent2"><span class="glyph">•</span>Heterozygosity for prothrombin G20210A and a positive family history of VTE in a family member who also carries prothrombin G20210A</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatives to estrogen-containing contraceptives are also favored for prothrombin G20210A heterozygous individuals with a negative family history of VTE. However, they may reasonably choose an estrogen-containing contraceptive if they lack other VTE risk factors. If an oral estrogen-containing contraceptive is used, we use one with a low estrogen dose. (See  <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias", section on 'Choice of estrogen-progestin oral contraceptive'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supporting evidence and contraceptive recommendations are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias"</a>.)</p><p></p><p>Similar considerations apply for other uses of estrogen-containing contraceptives such as acne or dysmenorrhea. (See  <a class="medical medical_review" href="/z/d/html/129467.html" rel="external">"Acne vulgaris: Management of moderate to severe acne in adolescents and adults", section on 'Oral hormonal therapies'</a> and  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment"</a>.)</p><p class="headingAnchor" id="H3282891383"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Pregnancy is a hypercoagulable state; VTE risk is highest in the first six weeks postpartum. The risk is increased in individuals with prothrombin G20210A (<a class="graphic graphic_table graphicRef119942" href="/z/d/graphic/119942.html" rel="external">table 4</a>), although the increase is generally not considered sufficient to justify systemic anticoagulation. Our approach to prophylaxis is summarized in the table (<a class="graphic graphic_table graphicRef95707" href="/z/d/graphic/95707.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who have not had a prior VTE and are found to be heterozygous for prothrombin G20210A, management of pregnancy and postpartum is mostly similar to the general population. We do not provide routine prophylactic anticoagulation, but anticoagulation may be appropriate for individuals with additional risk factors such as a strong family history of VTE, immobility, or cesarean delivery, or other surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who are homozygous for prothrombin G20210A or double heterozygotes for prothrombin G20210A plus another thrombophilic variant (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>), we generally use intermediate-dose or low-dose heparin antepartum and intermediate-dose heparin postpartum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For prothrombin G20210A heterozygotes who have a cesarean delivery, we provide two weeks of postpartum prophylactic dose anticoagulation in addition to standard pneumatic compression while in the hospital.</p><p></p><p>Supporting evidence and further discussion is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Prevention of VTE'</a>.)</p><p>Considerations for individuals with a prior VTE or early pregnancy morbidity are discussed below. (See <a class="local">'People with VTE'</a> below and <a class="local">'Pregnancy morbidity'</a> below.)</p><p class="headingAnchor" id="H2911264137"><span class="h3">Airline travel</span><span class="headingEndMark"> — </span>Airline travel is likely associated with an increased risk of VTE, especially over the course of longer flights (more than four to six hours).</p><p>For healthy people who are traveling by airplane for more than four hours, we typically recommend frequent ambulation (eg, every one to two hours) and/or calf and thigh muscle stretching. For those who place a high value on reducing VTE risk, we suggest below-the-knee graduated compression stockings. We generally do not recommend prophylactic anticoagulation with low molecular weight heparin or a direct oral anticoagulant. (See  <a class="medical medical_review" href="/z/d/html/101332.html" rel="external">"Prevention of venous thromboembolism in adult travelers"</a>.)</p><p>Some individuals may ask about the value of taking low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. We do not recommend this, given the lack of supporting data for its benefit. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Asymptomatic individuals'</a>.)</p><p class="headingAnchor" id="H3080696277"><span class="h1">PEOPLE WITH VTE</span><span class="headingEndMark"> — </span>For individuals with venous thromboembolism (VTE), heterozygosity for prothrombin G20210A generally does not affect management decisions regarding the use of anticoagulation, choice of anticoagulant, or duration of therapy (<a class="graphic graphic_algorithm graphicRef123067" href="/z/d/graphic/123067.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a> and  <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults"</a>.)</p><p>Once someone has an unprovoked VTE, heterozygosity for prothrombin G20210A plays little role in predicting the risk of recurrence, which is already high in those without hereditary thrombophilia; the presence of prothrombin G20210A confers less than a twofold increase in risk relative to someone with a prior VTE without the variant. (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'VTE recurrence risk'</a>.)</p><p>An exception is an individual who is homozygous for prothrombin G20210A or double heterozygous for prothrombin G20210A plus another thrombophilic variant (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>), which are considered high-risk thrombophilias; such patients may warrant indefinite anticoagulation following a first provoked VTE. </p><p class="headingAnchor" id="H3566891752"><span class="h1">PREGNANCY MORBIDITY</span><span class="headingEndMark"> — </span>It is unclear whether prothrombin G20210A increases the risk of spontaneous abortion, stillbirth, or fetal loss, with most prospective studies not finding an association. </p><p>Preeclampsia does not appear to be more common with prothrombin G20210A.</p><p>Individuals with pregnancy morbidity who are found to carry prothrombin G20210A should be evaluated by their obstetrician to determine the likely cause(s) of the pregnancy morbidity. (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Adverse pregnancy outcome risk'</a> and  <a class="medical medical_review" href="/z/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a>.)</p><p class="headingAnchor" id="H860637937"><span class="h1">CONSIDERATIONS FOR RELATIVES</span><span class="headingEndMark"> — </span>Routine testing of first-degree relatives of an individual with prothrombin G20210A is controversial and may not be indicated, especially if the family history is negative for venous thromboembolism (VTE). </p><p>For those with questions, referral to a hematologist or genetic counselor may be helpful.</p><p>Individuals with the variant should share this information with their first-degree relatives, who can discuss the risks and benefits of knowing their status with their own clinicians and come to individual decisions about whether to be tested.</p><p>We are most likely to find value in testing at-risk relatives if they are considering use of an estrogen-containing contraceptive, if there is a strong family history of VTE, or if the tested individual is homozygous for the variant or double heterozygous for prothrombin G20210A and another inherited thrombophilia (<a class="graphic graphic_table graphicRef108016" href="/z/d/graphic/108016.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A", section on 'Testing of first-degree relatives'</a> and  <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a>.)</p><p class="headingAnchor" id="H153262531"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H4283743226"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited thrombophilias</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical implications of prothrombin G20210A – (See  <a class="medical medical_review" href="/z/d/html/1359.html" rel="external">"Prothrombin G20210A"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Screening in asymptomatic individuals – (See  <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Contraception – (See  <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">"Contraception: Counseling for women with inherited thrombophilias"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy – (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism (VTE) prophylaxis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hospitalization – (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Orthopedic surgery – (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Other surgeries – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy – (See  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Cesarean delivery – (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Thromboembolism prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General concepts</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G&gt;A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2018; 20:1489.</a></li></ol></div><div id="topicVersionRevision">Topic 122113 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297698" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G&gt;A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
